The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

III.a

Alveolar hemorrhage (AH), diffuse AH (DAH)

Publications

Turan T, Sayın MR, Kul S, Akyüz AR

Be aware of misdiagnosis tied to COVID-19 focusing: a case report of abciximab-induced alveolar haemorrhage thought to be SARS-CoV-2 in a patient with ST-segment elevation myocardial infarction.

European heart journal. Case reports. 2020;4(6):1-6

Choi AW, Blair JE, Flaherty JD

Abciximab-induced alveolar hemorrhage treated with rescue extracorporeal membranous oxygenation.

Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions. 2015;85(5):828-31

Conrotto F, Scacciatella P, Usmiani T, Grasso C, Ebrille E, D'Amico M, Marra S

Pulmonary hemorrhage and acute pulmonary thromboembolism after abciximab administration.

The American journal of emergency medicine. 2013;31(2):450.e1-2

Mikkilineni H, Bruhl SR, Colyer WR, Pandya U

A retrospective analysis and case series of glycoprotein IIb/IIIa inhibitor associated diffuse alveolar hemorrhage: two case reports.

Cases journal. 2009;2:8553

Vizzardi E, D'Aloia A, Zanini G, Antonioli E, Pedrinazzi C, Raddino R, Dei Cas L

A case report of alveolar haemorrhage associated with severe thrombocytopenia induced by abciximab infusion in a patient with an acute coronary syndrome.

Internal and emergency medicine. 2008;3(4):345-7

Conley M, Patino G, Romick B, Almaleh M, Campbell C, Hawkins K, Moore S, Allan P

Abciximab-induced alveolar hemorrhage after percutaneous coronary intervention.

The Canadian journal of cardiology. 2008;24(2):149-51

Usman MH, Shah MA, ul-Islam T, Adenwalla HN, Rahman F, Baqir M, Altaf M, Venkataraman R, Cherayil M, Berger S

Abciximab and fatal pulmonary hemorrhage.

Heart & lung : the journal of critical care. 2006;35(6):423-6

Iskandar SB, Kasasbeh ES, Mechleb BK, Garcia I, Jackson A, Fahrig S, Albalbissi K, Henry PD

Alveolar hemorrhage: an underdiagnosed complication of treatment with glycoprotein IIb/IIIa inhibitors.

Journal of interventional cardiology. 2006;19(4):356-63

Tan HC, Low A, Ng KS, Budiono B, Sutandar A, Chia BL, Lim YT

Fatal pulmonary haemorrhage with the combined use of abciximab and fibrinolytic agent.

Singapore medical journal. 2002;43(11):587-9

Choi RK, Lee NH, Lim DS, Hong Sk, Hwang HK

Pulmonary hemorrhage after percutaneous coronary intervention with abciximab therapy.

Mayo Clinic proceedings. 2002;77(12):1340-3

Kalra S, Bell MR, Rihal CS

Alveolar hemorrhage as a complication of treatment with abciximab.

Chest. 2001;120(1):126-31

Ali A, Patil S, Grady KJ, Schreiber TL

Diffuse alveolar hemorrhage following administration of tirofiban or abciximab: a nemesis of platelet glycoprotein IIb/IIIa inhibitors.

Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions. 2000;49(2):181-4

Khanlou H, Tsiodras S, Eiger G, Abousy K, Goldberg S, Nakhjavan F, Yazdanfar S

Fatal alveolar hemorrhage and Abciximab (ReoPro) therapy for acute myocardial infarction.

Catheterization and cardiovascular diagnosis. 1998;44(3):313-6